WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Medtox Scientific, Inc. (“Medtox” or the “Company”) (NASDAQ GS: MTOX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Laboratory Corporation of America Holdings (“Laboratory Corporation”) (NYSE: LH) in a transaction valued at approximately $241 million.
Click here to learn more: http://www.rigrodskylong.com/investigations/medtox-scientific-inc-mtox.
Under the terms of the proposal, public shareholders of Medtox will receive $27.00 per share in cash for each share of Medtox they own. The investigation concerns whether Medtox’s board of directors failed to adequately shop the Company and obtain the best possible price for Medtox’s shareholders before entering into an agreement with Laboratory Corporation.
If you own the common stock of Medtox and purchased your shares before June 4, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Peter Allocco at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530 toll free at (888) 969-4242, by e-mail to email@example.com, or at: http://www.rigrodskylong.com/investigations/medtox-scientific-inc-mtox.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.